Teva Pharmaceutical Industries Limited Sponsored ADR is a premium stock of StocksGuide. Please log in to activate an alert for Teva Pharmaceutical Industries Limited Sponsored ADR.
Register for Free
Please register for free to add Teva Pharmaceutical Industries Limited Sponsored ADR to your portfolio.
Teva hosts its first R&D Day, sharing pipeline updates and a target of $6–7 billion in innovative medicines revenue by 2030 as a high-velocity biopharma.
Teva Pharmaceutical Industries expects to grow in 2027 despite the US inflation reduction act that will cap prices for its top branded drug Austedo to treat Huntington's Disease and Tardive Dyskinesia, CEO Richard Francis said on Tuesday.
Israeli drugmaker Teva Pharmaceutical Industries, reported on Tuesday a higher-than-expected rise in third-quarter profit, helped by strong sales of a trio of its own drugs to offset declines in copycat medicines.
Teva to obtain U.S. commercialization rights for two immunology biosimilars: ETICOVO® upon close and infliximab-abda in Q3 2027 Collaboration combines Samsung Bioepis' biosimilar expertise with Teva's commercial capabilities Agreement expands collaboration with Samsung Bioepis, strengthening Teva's generics powerhouse and biosimilars portfolio as part of its Pivot to Growth strategy TEL AVIV, I...
Teva said on Monday it was discontinuing its mid-stage neurodegenerative disorder study due to a low probability of the study meeting its main goal if continued.
Teva acquires worldwide rights to BXCL501, expanding its neuroscience pipeline with a potential at-home treatment for agitation currently under FDA review
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.